RT Journal Article
T1 Dalbavancin is a novel antimicrobial against Gram-positive pathogens: clinical experience beyond labelled indications.
A1 Núñez-Núñez, María
A1 Casas-Hidalgo, Inmaculada
A1 García-Fumero, Ricardo
A1 Vallejo-Rodríguez, Inmaculada
A1 Anguita-Santos, Francisco
A1 Hernández-Quero, José
A1 Cabeza-Barrera, José
A1 Ruiz-Sancho, Andrés
K1 clinical pharmacy
K1 dalbavancin
K1 infectious diseases
K1 new antimicrobials
AB Very limited labelled indications have been approved for the newer antimicrobials. Data on the clinical uses, efficacy and safety of dalbavancin are scarce, thus here we sought to describe our clinical experience. 16-month observational prospective study was performed. 19 (86%) were used under off-label indications. 10 (46%) for osteoarticular infections, 5 (23%) bloodstream infections and 3 (14%) endocarditis. To highlight, one patient received dalbavancin as long-term suppressive therapy. Most frequent use reasons were promptly hospital discharge, 11 (65%), and the presence of resistant organisms involving limited treatment options, 5 (23%). Successful outcome was observed in >95% of the patients and only 1 (4.5%) adverse event was reported. Further evidence beyond labelled indications is urgently needed. Despite the limitations, dalbavancin appears to be a safe and efficient option for adult patients who have tried and/or failed other therapies due to multidrug-resistant Gram-positive organisms.
SN 2047-9956
YR 2018
FD 2018-11-26
LK https://hdl.handle.net/10668/26136
UL https://hdl.handle.net/10668/26136
LA en
DS RISalud
RD Apr 6, 2025